Adrenomyeloneuropathy (AMN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 The adult-onset of X-linked Adrenoleukodystrophy, called as Adrenomyeloneuropathy (AMN), is characterized by ABCD1 gene mutation, which results in impaired peroxisome function with an accumulation of very long chain fatty acids (VLCFA) and demyelination. Adrenomyeloneuropathy (AMN) is mild, progresses slowly and is associated with an average life span in the ages of 21-35 years. The main symptoms include stiffness, weakness, paralysis of the lower limbs and loss of coordination. Women who are carriers of the disease occasionally experience the same symptoms along with ataxia, hypertonia, mild peripheral neuropathy and urinary problems. Individuals with X-ALD who reach their adulthood develop myelopathy and neuropathy, leading to AMN, in the age group of 30-40 years. The spinal cord and limber nerves are the only areas that initially exhibit symptoms. Before MR imaging was available, AMN was often misdiagnosed as multiple sclerosis or hereditary spastic paraparesis (HSP). In the majority of cases, this phenotype progresses gradually, resulting in severe motor disability in the lower limbs over one to two decades, but only mild or no noticeable deficits in the arms and hands.

·       The diagnosed incidence of Adrenomyeloneuropathy (AMN) varies between 0.57 to 1.05 cases per 100,000 population in the USA.

 

Thelansis’s “Adrenomyeloneuropathy (AMN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adrenomyeloneuropathy (AMN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Adrenomyeloneuropathy (AMN) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Adrenomyeloneuropathy (AMN) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Adrenomyeloneuropathy (AMN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Adrenomyeloneuropathy (AMN), Adrenomyeloneuropathy (AMN) market outlook, Adrenomyeloneuropathy (AMN) competitive landscape, Adrenomyeloneuropathy (AMN) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)